Research library

1,768 reports · By date added

Citi: HitGen’s third-quarter revenue rises 43%: core platforms expand as AI projects begin shortening drug discovery timelines

Growth across multiple drug discovery service lines and an improved revenue mix drove higher third-quarter revenue and margins at HitGen. Citi raised its earnings forecasts for the next three years, but continued R&D investment, the financing environment for clients and the pace of commercialization of new platforms will still affect the realization of profits.